Compugen Ltd. (NASDAQ:CGEN) traded today at a new 52-week low of $6.64. So far today approximately 216,000 shares have been exchanged, as compared to an average 30-day volume of 1 million shares.
Compugen Ltd is a therapeutic discovery company. It is involved in the business of using its predictive discovery infrastructure to identify novel drug targets and develop biologics. The firm’s therapeutic pipeline mainly consists of early-stage immuno-oncology programs aimed at harnessing the immune system to fight cancer. It focuses on immune checkpoint target candidates which are predicted to serve drug targets for cancer immunotherapies addressing various cancer types and also autoimmune diseases.
Compugen Ltd. (NASDAQ:CGEN) has potential upside of 20.3% based on a current price of $6.86 and analysts’ consensus price target of $8.25.
Compugen Ltd. share prices have moved between a 52-week high of $19.90 and the current low of $6.64 and are currently at $6.86 per share.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer